600518 Kangmei Pharmaceutical
- 1.95
- +0.01+0.52%
Kangmei Pharmaceutical News
Express News | ST Kangmei: Received court enforcement ruling
Subdued Growth No Barrier To Kangmei Pharmaceutical Co., Ltd.'s (SHSE:600518) Price
Kangmei Pharmaceutical Co., Ltd.'s (SHSE:600518) price-to-sales (or "P/S") ratio of 5.5x may not look like an appealing investment opportunity when you consider close to half the companies in the Phar
Kangmei Pharmaceutical Logs Profit in Q1
Kangmei Pharmaceutical (SHA:600518) returned to an attributable profit of 7.5 million yuan, or 0.001 yuan per share, in the first quarter, according to a Tuesday filing with the Shanghai Stock Exchang
ST Kangmei (600518.SH) announced first-quarter results, net profit of 7.4713 million yuan
ST Kangmei (600518.SH) released its report for the first quarter of 2024. The company achieved operating income of 1 during the reporting period...
The Strong Earnings Posted By Kangmei Pharmaceutical (SHSE:600518) Are A Good Indication Of The Strength Of The Business
Even though Kangmei Pharmaceutical Co., Ltd. (SHSE:600518 ) posted strong earnings, investors appeared to be underwhelmed. We have done some analysis and have found some comforting factors beneath th
Kangmei Pharmaceutical Co., Ltd. (SHSE:600518) On An Uptrend: Could Fundamentals Be Driving The Stock?
Kangmei Pharmaceutical's (SHSE:600518) stock up by 6.1% over the past three months. Given that stock prices are usually aligned with a company's financial performance in the long-term, we decided to
Kangmei Pharmaceutical Returns to Profit in 2023; Shares Decline 4%
Kangmei Pharmaceutical (SHA:600518) returned to an attributable profit of 102.5 million yuan in 2023 from a loss of 2.69 billion yuan in 2022, according to a Monday filing with the Shanghai bourse. Ea
ST Kangmei (600518.SH) announced its 2023 annual results, with net profit of 103 million yuan, turning a loss into a profit
ST Kangmei (600518.SH) released its 2023 annual report. The company's revenue was 4.884 billion yuan, up 16.60% year on year; net profit attributable to shareholders of listed companies was 103 million yuan, turning a loss into a profit; net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss was 753 million yuan, and losses narrowed; and basic earnings per share were 0.01 yuan/share.
Court Dismisses Winding-Up Petition Against Kangmei Pharma's Unit
A Chinese court dismissed Foshan Xiangying Furniture Manufacturing's winding up petition against Kangmei Pharmaceutical's (SHA:600518) unit, Kangmei Traditional Chinese Medicine City (Puning), the pha
Retail Investors Are Kangmei Pharmaceutical Co., Ltd.'s (SHSE:600518) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥3.7b Last Week
Key Insights Significant control over Kangmei Pharmaceutical by retail investors implies that the general public has more power to influence management and governance-related decisions A total of 25
Express News | ST Kangmei: The company expects net profit of 90 million yuan to 135 million yuan in 2023, turning a loss into a profit
Is Kangmei Pharmaceutical (SHSE:600518) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' So it might be obvious
Private Companies Own 32% of Kangmei Pharmaceutical Co., Ltd. (SHSE:600518) Shares but Individual Investors Control 55% of the Company
Key Insights Kangmei Pharmaceutical's significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 25 investors have a
ST Kangmei (600518.SH) released the first three quarter results, with a net loss of 148 million yuan
ST Kangmei (600518.SH) released the report for the first three quarters of 2023, with the company's revenue of 3,534 billion...
ST Kangmei (600518.SH): Sales currently do not involve medicinal alcohol-related products
Glonghui September 15 | ST Kangmei (600518.SH) said on the investor interactive platform that the company achieved operating income of 2,377 billion yuan in the first half of 2023, an increase of 33.62% over the previous year, and net profit attributable to shareholders of listed companies was -126 million yuan, a year-on-year loss reduction of 35.67%. The business development situation in the first half of the year was steady, moderate and positive, and overall sales performance increased significantly and losses decreased significantly compared to last year. Up to now, the company has established in-depth business partnerships with more than 1,100 medical institutions and more than 40,000 pharmacy chains nationwide, and has a nationwide marketing layout. The company's core business is traditional Chinese medicine
ST Kangmei (600518.SH) released semi-annual results, with a net loss of 126 million yuan, narrower than the previous year
ST Kangmei (600518.SH) disclosed the 2023 semi-annual report. The company achieved revenue of 23.7 during the reporting period...
ST Kangmei (600518.SH): Court ruled inadmissible the applicant's bankruptcy liquidation of a wholly-owned subsidiary
GLONGHUI, August 4, | ST Kangmei (600518.SH) announced that Puning Traditional Chinese Pharmacy today received the Jieyang Intermediate Court (2023) Guangdong No. 5 “Civil Ruling”. The Jieyang Intermediate Court believes that Zhongke Heng has filed for bankruptcy of Puning Traditional Chinese Pharmacy and needs to prove that it is unable to pay off all of its maturing debts and that its assets are insufficient to pay off all of its debts or that it clearly lacks solvency. In this case, the evidence in the case was insufficient to prove the fact that Puning Chinese Pharmacy had assets insufficient to pay all of its debts or that it clearly lacked solvency. Therefore, the Jieyang Intermediate Court did not support the claim that Zhongke Heng filed for bankruptcy and liquidation of Puning Chinese Pharmacy.
Kangmei Pharmaceutical Co., Ltd. (SHSE:600518) Stock Most Popular Amongst Retail Investors Who Own 54%, While Private Companies Hold 32%
Key Insights Kangmei Pharmaceutical's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public The top 25 shareholders own 46% of
ST Kangmei (600518.SH): Withdrawal of Application to Revoke Company Shares and Other Risk Warnings
Gelonghui, June 13, 丨 ST Kangmei (600518.SH) announced that the company applied to the Shanghai Stock Exchange to withdraw the “Other Risk Warning” on April 29, 2023. After careful consideration by the company, it has now been decided to withdraw the application for the company's shares to withdraw other risk warnings.
Is Kangmei Pharmaceutical (SHSE:600518) Using Debt Sensibly?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' When we think about how
Analysis
Price Target
No Data
